title: [Reversible inhibitor of MAO-A(RIMA)].
abstract: Monoamine oxidase(MAO) inhibitors had been used in the treatment of depression since 1950s, but there is no MAO inhibitor available clinically in Japan. Liver dysfunction and tyramine's effect are main problems with MAO inhibitors. Reversible inhibitors of MAO-A(RIMA), new and improved MAO inhibitors, were developed and are widely used in Europe. RIMA causes less tyramine's effect and less liver dysfunction than classical MAO inhibitors do. Moclobemide, a RIMA, is under development in Japan(Phase II). An introduction of RIMA in Japan will be useful for the treatment of refractory depression and other anxiety disorders. We discussed pharmacological properties, clinical efficacy and safety of RIMA.
authors.affiliation: Department of Psychiatry, Neural Function, Hokkaido University Graduate School of Medicine.
authors.forename: T
authors.initials: T
authors.lastname: Inoue
authors.forename: T
authors.initials: T
authors.lastname: Koyama
mesh_terms: D001008:Anxiety Disorders / Q000188:drug therapy; D015306:Biogenic Monoamines / Q000378:metabolism / Q000502:physiology; D003863:Depression / Q000188:drug therapy; D006801:Humans; D015201:Meta-Analysis as Topic; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D009435:Synaptic Transmission / Q000187:drug effects
chemical_list: D015306:Biogenic Monoamines; D008996:Monoamine Oxidase Inhibitors